Stock Events

Stock Events

Ascendis Pharma A/S 

€174
24
-€3-1.69% Monday 09:30

Statistics

Day High
174
Day Low
173
52W High
185
52W Low
115
Volume
25
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-2.5
-1.89
-1.29
-0.68
Expected EPS
-1.42
Actual EPS
-0.93

Financials

-103.97%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
727.28MRevenue
-756.17MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow A71.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer competes in various therapeutic areas including those targeted by Ascendis Pharma's endocrinology and oncology pipeline.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a leader in diabetes and growth disorders, directly competing with Ascendis Pharma's growth hormone deficiency treatments.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a strong presence in endocrinology, particularly in growth hormone and diabetes treatments, competing with Ascendis' portfolio.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals competes in the development of treatments for genetic disorders, a key area of focus for Ascendis Pharma.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on rare diseases, including areas like growth disorders, directly competing with Ascendis' therapies.
Opko Health
OPK
Mkt Cap1.04B
OPKO Health has a division focused on pharmaceuticals, including growth hormone treatments, making it a direct competitor.
Ligand Pharmaceuticals
LGND
Mkt Cap3.73B
Ligand Pharmaceuticals' technology platforms and partnerships enable it to compete in the development of endocrinology and oncology drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biopharmaceutical space with a focus on innovative treatments, overlapping with Ascendis' therapeutic areas.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurological and neurodegenerative diseases but its expansion into other biopharmaceutical areas can position it as a competitor.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's broad focus on biotechnology treatments for various diseases, including bone health and oncology, places it in competition with Ascendis Pharma.

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/" for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Show more...
CEO
Mr. Jan Moller Mikkelsen
Employees
797
Country
DK
ISIN
US04351P1012
WKN
000A14M6X

Listings

MX
MX
ASNDN.MX
XNAS
US
ASND
F
DE
A71.F
SA
BR
A1SN34.SA

0 Comments

Share your thoughts

FAQ

What is Ascendis Pharma A/S stock price today?▼
The current price of A71.F is €174 EUR — it has decreased by -1.69% in the past 24 hours. Watch Ascendis Pharma A/S stock price performance more closely on the chart.
What is Ascendis Pharma A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ascendis Pharma A/S stocks are traded under the ticker A71.F.
Is Ascendis Pharma A/S stock price growing?▼
A71.F stock has risen by +0% compared to the previous week, the month change is a -2.79% fall, over the last year Ascendis Pharma A/S has showed a +42.62% increase.
What is Ascendis Pharma A/S revenue for the last year?▼
Ascendis Pharma A/S revenue for the last year amounts to 727.28M EUR.
What is Ascendis Pharma A/S net income for the last year?▼
A71.F net income for the last year is -756.17M EUR.
How many employees does Ascendis Pharma A/S have?▼
As of February 02, 2026, the company has 797 employees.
In which sector is Ascendis Pharma A/S located?▼
Ascendis Pharma A/S operates in the Health Care sector.
When did Ascendis Pharma A/S complete a stock split?▼
Ascendis Pharma A/S has not had any recent stock splits.
Where is Ascendis Pharma A/S headquartered?▼
Ascendis Pharma A/S is headquartered in Hellerup, DK.